The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFFWD.L Regulatory News (FFWD)

  • There is currently no data for FFWD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Update

14 Nov 2007 07:01

London Asia Capital PLC14 November 2007 14 November 2007 LONDON ASIA CAPITAL PLC ("London Asia" or "the Company") Business Update London Asia Capital PLC, the AIM listed (code LDC) Asian focused investmentgroup, is pleased to give an update on recent developments across the group. London Asia Chinese Private Equity Fund ("the Fund") The Fund, advised by London Asia, recommenced trading on AIM (code LCP) on 1November, following the release of its audited accounts to 31 March 2007, whichshowed profits of £18.4 million and net assets up 33% in its first year ofoperation, after accrual of a performance related fee ("the Performance Fee") toLondon Asia of £3.3 million. The calculation of the Performance Fee is based onthe increase in the Fund's net assets and various other criteria, is payableonly on realisation of individual assets by the Fund, and could be reduced inthe event that there was any subsequent fall in the net asset value per share ofthe Fund. The Company therefore does not anticipate accounting for thePerformance Fee until it receives the actual cash payment or other confirmationfrom the Fund of the exact amount receivable, without any clawback orconditions, which means there is unlikely to be any significant amountsaccounted for in this financial year. The fund management team working on theFund is entitled to 50% of the Performance Fee due to the Company. In addition to the Performance Fee, London Asia receives a management fee of 2%of the net assets of the Fund, which based on the increase in net assets for theFund to 31 March 2007, will generate an additional £0.3 million p.a of incomefor the Company starting 1 April 2007. Share Buy-backs The recent successful offer to shareholders has generated cash and realisedprofits for the Company, putting it in a position to be able to buy-back its ownshares. The Company has authority to buy back up to 10% of its ordinary sharecapital, and intends to implement a programme to acquire its own shares,addressing the gap between reported net asset value per share and current shareprice. LAC Zhongying ("Zhongying") The Company has reached agreement with the other shareholders in Zhongying tosell its minority stake to the other Zhongying shareholders for cash at theoriginal cost of approximately £12.4 million. Zhongying has fully invested allits capital in a number of transactions, primarily in the energy, environmentand financial services sectors, but, as a result of various changes in theregulations in China, has encountered significant problems achieving itsoriginal business plan of acquiring and exploiting a series of financialservices licences. Restrictions imposed by the Chinese Government on foreignersentering the financial services sector have also prevented the Company frompartnering with, or bringing in as shareholders, non Chinese financial servicesgroups, which has limited our ability to find buyers and realise the full valueof the investment. Whilst the Board considers Zhongying a good long terminvestment, our minority stake gives us little control over the ability torealise value from the investment in the short term. The Board believes that thecapital freed up by the sale of the stake can be better deployed in thefinancial services businesses acquired earlier this year and in China FinancialServices, where London Asia holds a 48% stake. Yellow River Securities ("YRS") YRS, the Company's 40% owned securities trading business, has been active in thebooming Hong Kong stock market. It has invested over US$1 million over the lastfew months, which has generated an unrealised profit of over US$1 million, giventhe strong performance of the Hong Kong stock market recently. YRS's strategy isto take short term positions in listed stocks, and it is actively trading itspositions to realise the paper profit. Further investment in portfolio companies The Board has been reviewing the Company's existing investment portfolio toidentify ways of accelerating value, make better use of the Company's growingcash resources, and take advantage of the scarcity of deal flow and highvaluations in the region as a result of restrictions on the investment by nonChinese into Chinese assets, and the recognition by both local and overseasinvestors of the potential for Chinese equities as China continues its strongeconomic growth and development. The Board has identified two businesses within the existing portfolio that itbelieves are suitable for immediate follow-on financing and flotation in thenear future, and is working with the companies to determine whether thebusinesses are suitable for listing on NYSE Euronext's Alternext stock market,where we were recently approved as a sponsor for listings. The Board believes several of the other portfolio businesses would benefit fromadditional injections of capital to bring them to a size where they could betaken to capital markets, sold on in a trade sale or refinanced. The Board isdetermining whether London Asia should invest additional funds in thesebusinesses, or third party funding be sought, based on the projected timing ofcash inflows from realisation of existing assets, and the needs of the portfoliobusinesses. Jack Wigglesworth, London Asia Chairman, commented: "The success of the Funddemonstrates the upside potential of our investment portfolio. Part of thereason for the relatively greater success of the Fund portfolio relative to ourown, has been that the investments made by the Fund have been in largerbusinesses than those which the Company has historically invested in. Whilst ourown investments are demonstrating good organic growth, in order to get to a sizewhere they can be exited at the sort of valuations being achieved by Chineseassets in the current market, they will need to make acquisitions to boost thesize of their revenue and profits. The Board is therefore looking at which ofour portfolio businesses would benefit most from a further injection of ourcapital to get them closer to the point where we can achieve an exit. "Our strategy is to apply the increasing levels of cash being generated by ouroperations to reduce the gap between the Company's assets and share price, andaccelerate the realisation of our investment portfolio through furtherinvestment. New investments will be made in businesses where we can exercise alevel of control and have an economically significant stake, both within ourtraditional Greater China region, and in the other areas of Asia where LAL isexpanding. "The decision earlier this year to create a number of operating businesses partowned by London Asia and part owned by the management of the new businesses isdemonstrating results, as we are able to expand much more rapidly into newareas, such as securities trading through YRS, than was previously possible wheneverything had to be financed and all management came from London Asia." For further information please visit www.londonasiacapital.com or contact: Cecilia Wong John West/Andrew Dunn Jonathan WrightLondon Asia Capital plc Tavistock Communications Seymour PierceTel: +852 2251 8373 Tel: 020 7920 3150 Tel: 020 7107 8050 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th Feb 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
18th Feb 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
11th Feb 20207:00 amRNSUpdated Key Information Document
31st Jan 20201:30 pmRNSInvestee Company Update: Portage Biotech Inc.
8th Jan 20207:00 amRNSDisposal of Interest in Cryptologic Corp
7th Jan 20207:00 amRNSBoard Appointment
3rd Jan 20201:15 pmRNSInvestee Company Update: Portage Biotech Inc.
11th Dec 20197:00 amRNSHalf-year Report
5th Dec 20192:45 pmRNSTR-1 Notification
19th Nov 20197:00 amRNSLorne Abony appointed as Chairman of EMMAC
16th Oct 20197:00 amRNSInvestee Company Update: EMMAC Life Sciences
15th Oct 20197:00 amRNSInvestee Company Update: Factom inc.
10th Oct 20199:25 amRNSResult of 2019 AGM
27th Sep 20194:31 pmRNSDirector Dealing in the Company
27th Sep 20197:00 amRNSInvestee Company Update : Fralis LLC (Leap Gaming)
26th Sep 201911:21 amRNSInvestee Company Update : Cryptologic Corp
16th Sep 201911:52 amRNSTR-1 Notification of major holdings
11th Sep 20198:00 amRNSResults for the year ended 31st March 2019
11th Sep 20198:00 amRNSNotice of 2019 Annual General Meeting
22nd Aug 201912:01 pmRNSDirectorate Change
19th Aug 20199:23 amRNSJuvenescence closes Series B funding
12th Aug 20193:02 pmRNSInvestee Company Update-Cryptologic issues loan
12th Aug 201910:11 amRNSPortage Trading Suspended
6th Aug 20194:42 pmRNSInvestee Company Update: Cryptologic Corp
30th Jul 201911:07 amRNSSAFE Agreement with Factom, Inc. Extended
25th Jul 20198:17 amRNSFactom Inc SAFE Agreement temporary extension
18th Jul 201911:20 amRNSInvestee Company Update: Regent Pacific on Yooya
16th Jul 20199:13 amRNSInvestee Company Update:EMMAC acquires Terre Verde
11th Jul 20193:00 pmRNSDisposal of interest in Intensity Therapeutics Inc
9th Jul 201910:51 amRNSInvestee Company Update: EMMAC enters new Market
26th Jun 20198:56 amRNSInvestee Company Update: Intensity Therapeutics
29th May 20193:43 pmRNSInvestee Company Update: Offer for Yooya
13th May 201910:21 amRNSDisposal of interest in Vemo Education Inc.
18th Apr 20197:00 amRNSInvestee Company Update: Intensity Therapeutics
4th Apr 20199:51 amRNSTR1 - Correction
3rd Apr 20194:00 pmRNSTR:1 Regent Mercantile Holdings Limited
20th Mar 201911:00 amRNSCompletion of £2 million investment in EMMAC
7th Mar 20194:03 pmRNS£2 million investment in EMMAC Life Sciences
15th Jan 20193:45 pmRNSJuvenescence Series B Funding
3rd Jan 201911:47 amRNSBoard Appointment
12th Dec 201812:52 pmRNSHalf-year Report
3rd Dec 20187:00 amRNSInvestee Company Update: Factom and Yooya
14th Nov 20181:31 pmRNSInvestee Company Update: Factom Inc
22nd Oct 201812:24 pmRNSIntensity Therapeutics Inc Update
12th Sep 20186:12 pmRNSResult of AGM
10th Sep 20189:16 amRNSHolding(s) in Company
22nd Aug 20188:08 amRNSDirector Dealing
3rd Aug 201812:48 pmRNSShareholder update
3rd Aug 20188:00 amRNSPlacing
1st Aug 201812:05 pmRNSResponse to Media Speculation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.